Notice Regarding Partial Amendment to the Articles of Incorporation

Tokyo, Japan and Cambridge, UK, 14 February 2025 – Nxera Pharma Co., Ltd. ("Nxera" or "the Company"; TSE 4565) today announces that its Board of Directors resolved to submit the proposal "Partial Amendments to the Articles of Incorporation" to the 35th Ordinary General Meeting of Shareholders scheduled to be held on 26 March 2025.

1. Reason for the amendment

With the enforcement of the "Act for Partial Revision of the Act on Strengthening Industrial Competitiveness, etc." (Act No. 70 of 2021), listed companies can hold general shareholders meetings without a defined location (so-called "Virtual-Only General Meeting of Shareholders") under certain conditions by stipulating so in their Articles of Incorporation.

Given the purpose of the legislation and the advancement of society digitalization, and to reduce the risk of holding meetings in the event of major disasters, we believe that expanding the methods of holding general meetings of shareholders so that we can respond flexibly to situations, will benefit all shareholders and propose establishing new Article 12, Paragraph 2 of the Articles of Incorporation.

For the amendment to the Articles of Incorporation, the Company received confirmation from the Minister of Economy, Trade and Industry and the Minister of Justice required under Article 66, Paragraph 1 of the Act on Strengthening Industrial Competitiveness (Act No. 98 of 2015).

2. Content of the Amendment

The proposed amendment is as follows.

(The underlined portions show the changes.)

Current Articles of Incorporation	Proposed Amendment
CHAPTER 3 GENERAL MEETING OF SHAREHOLDERS	CHAPTER 3 GENERAL MEETING OF SHAREHOLDERS
(Convocation)	(Convocation)
Article 12	Article 12
The Ordinary General Meeting of Shareholders of the Company shall be convened within three months after the end of each business year and an Extraordinary General Meeting of Shareholders shall be convened whenever necessary.	(Same as current provision)
(Newly established)	2. The General Meeting of Shareholders of the Company may be held as shareholders' meetings without a location.

3. Schedule

Date of General Meeting of Shareholders for the amendment and effective date of the amendments: 26 March 2025 (scheduled)

–END–

About Nxera Pharma

Nxera Pharma is a technology powered biopharma company, in pursuit of new specialty medicines to improve the lives of patients with unmet needs in Japan and globally.

In addition to several products being commercialized in Japan, we are advancing an extensive pipeline of over 30 active programs from discovery through to late clinical stage internally and in partnership with leading pharma and biotech companies. This pipeline is focused on addressing major unmet needs in some of the fastest-growing areas of medicine across neurology, GI and immunology, metabolic disorders and rare diseases, and leverages the power of our unique and industry leading GPCR-targeted structure-based drug discovery "NxWave™" platform to provide a sustainable source of best- or first-in-class candidates.

Nxera employs over 350 talented people at key locations in Tokyo and Osaka (Japan), London and Cambridge (UK), Basel (Switzerland) and Seoul (South Korea) and is listed on the Tokyo Stock Exchange (ticker: 4565).

For more information, please visit www.nxera.life
LinkedIn: @NxeraPharma | X: @NxeraPharma | YouTube: @NxeraPharma

Enquiries:

Nxera – Media and Investor Relations
Kentaro Tahara, VP Investor Relations and Corporate Strategy
Shinichiro Nishishita, VP Investor Relations, Head of Regulatory Disclosures
Maya Bennison, Communications Manager
+81 (0)3 5210 3399 | +44 (0)1223 949390 |IR@Nxera.life

MEDiSTRAVA (for International Media)
Mark Swallow, Frazer Hall, Erica Hollingsworth
+44 (0)203 928 6900 | Nxera@medistrava.com

Forward-looking statements

This press release contains forward-looking statements, including statements about the discovery, development, and commercialization of products. Various risks may cause Nxera Pharma Group's actual results to differ materially from those expressed or implied by the forward looking statements, including: adverse results in clinical development programs; failure to obtain patent protection for inventions; commercial limitations imposed by patents owned or controlled by third parties; dependence upon strategic alliance partners to develop and commercialize products and services; difficulties or delays in obtaining regulatory approvals to market products and services resulting from development efforts; the requirement for substantial funding to conduct research and development and to expand commercialization activities; and product initiatives by competitors. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statements. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.